Navigating Complex Logistics in Radiopharmaceutical Supply Chains

Published October 2026  | Author: Martin Davis, Leading Minds Network 

Key Takeaways 

• Radiopharmaceutical supply chains are a constant race against radioactive decay, making time the most critical constraint from isotope production through patient administration.
• Success depends on tight coordination among all supply chain stakeholders, including the patient.
• Commercial scaling presents new challenges around visibility, communication, training, contingency planning, and operational standardization.
• Real-time data sharing and orchestration platforms are emerging as essential tools, yet no single solution addresses the industry’s full complexity.
• Infrastructure readiness, site preparedness, regulatory compliance, and patient scheduling are major barriers to broader adoption and access.

Radiopharmaceutical therapies are rapidly changing the treatment landscape for cancer and other serious diseases. Yet unlike conventional pharmaceuticals, these therapies introduce a unique operational challenge: the clock begins ticking the moment a radioisotope is produced. Every stage of manufacturing, transportation, scheduling, and administration must be orchestrated with exceptional precision to ensure patients receive the right dose at the right time.

How Is the Radiopharma Supply Chain Defined by Time? 

Radiopharmaceuticals begin to decay immediately after isotope production. As Drew Ciembronowicz noted, no cold chain solution can stop radioactive decay. The industry is constantly operating against an unforgiving clock.

 Patient treatment sites must be ready to administer therapies within a window that may range from just a few hours to several days. 

Jessi Cravens compared the process to a block of ice that starts melting the moment it is created. From isotope production to manufacturing, transportation, and patient administration, literally every minute matters. Manufacturers must carefully balance timing to ensure isotopes arrive with precision.  

Why Are Traditional Pharmaceutical Logistics Not Sufficient? 

The panelists noted that radiopharmaceutical products cannot simply be inserted into conventional pharmaceutical distribution models.

These therapies, classified as radioactive hazardous materials, require specialized handling, regulatory compliance, chain-of-custody controls, and licensed receiving facilities. Every organization and individual that touches these shipments must meet strict qualification requirements, from manufacturing personnel and transportation providers to airport personnel and treatment sites.

To add to this complexity, standard transport models introduce risks that are unacceptable in radiopharmaceutical logistics. Delays at sorting facilities, customs checkpoints, airport handoffs, or delivery locations can compromise product viability and impact patient treatment schedules.

This creates a logistics environment where direct transportation routes, dedicated resources, and detailed contingency planning are imperative. 

Scaling from Clinical Trials to Commercial Operations 

One of the most significant challenges discussed during the session was the transition from clinical development to commercial scale.

Clinical trials often rely on a relatively small group of subject matter experts who understand every detail of the process and can react quickly when exceptions occur. Commercialization, however, requires teams, processes, and infrastructure capable of supporting hundreds of patients, multiple manufacturing schedules, and increasingly complex transportation networks.

Cravens noted that one of the first things to break down during scaling is organizational knowledge transfer. As therapies move toward commercial distribution, expertise must be expanded beyond a handful of specialists and embedded across entire operational teams.

According to the panelists, successful commercialization requires robust cross-functional communication, comprehensive training programs, and carefully documented processes that allow organizations to operate consistently at scale. 

What Is the Critical Role of Visibility and Orchestration? 

A major focus throughout the discussion was the importance of visibility across the entire patient journey.

Nancy Young stressed that effective coordination begins long before a product is shipped. Manufacturers, treatment centers, physicians, logistics providers, and patients all influence when and how a therapy is delivered. Treatment schedules must align with manufacturing capacity, isotope availability, physician access, and patient readiness.  

 Any disruption, whether related to weather, transportation delays, customs, staffing availability, or patient health changes, can ripple through the entire system. 

To address the challenges, the industry is increasingly exploring orchestration platforms that integrate data across manufacturers, logistics providers, and clinical sites. These solutions aim to provide real-time visibility into manufacturing schedules, inventory availability, transportation status, patient scheduling, and treatment readiness.

However, panelists agreed that no existing platform today fully addresses the industry’s needs. As a result, many organizations are developing customized orchestration solutions designed specifically for radiopharmaceutical workflows. 

Managing Chain of Custody and Last-Mile Risk 

The discussion also highlighted the unique chain-of-custody requirements associated with radioactive therapies.

Tracking is only part of it. Organizations must know exactly who handled a shipment, where custody changed hands, and whether package integrity was maintained throughout transit.

Ciembronowicz emphasized that radiopharmaceuticals cannot simply be delivered to loading docks or unsecured receiving areas. Shipments must be delivered directly to controlled, licensed environments with qualified personnel available to receive them.

Last-mile delivery presents additional challenges, particularly when treatments must be delivered during overnight hours or to sites undergoing operational changes. Transportation providers must account for vehicle readiness, driver qualifications, route planning, weather disruptions, equipment failures, and numerous other variables that can affect delivery performance. 

 Given the narrow treatment windows involved, contingency plans often need contingency plans of their own. 

The Patient Remains at the Center

While much of the discussion focused on operational complexity, panelists repeatedly returned to the patient experience. Many radiopharmaceutical patients are undergoing advanced cancer treatments and often face rapidly changing health conditions.

A patient who qualifies for treatment one week may become ineligible the next due to changes in blood counts or other clinical criteria. This creates challenges for manufacturers, treatment sites, scheduling, forecasting, and resource planning.

The panel emphasized the importance of educating patients about the therapy journey, ensuring they understand treatment timelines, attendance requirements, and the significance of keeping appointments. At the same time, treatment centers must maintain flexibility to accommodate inevitable changes while minimizing disruptions. 

Preparing for the Next Phase of Growth

Radiopharmaceuticals are rapidly expanding, with hundreds of therapies currently progressing through clinical development.

To support this growth, panelists identified several priorities for the next five years:

• Expanding treatment site readiness and specialized infrastructure.
• Increasing the number of trained and authorized healthcare professionals.
• Enhancing airport and transportation network capabilities for radioactive materials.
• Improving collaboration between manufacturers, logistics providers, and treatment sites.
• Developing interoperable data platforms that provide end-to-end visibility across the patient journey.
  

Ultimately, the panel agreed that no organization can solve these challenges alone. Success will require industry-wide collaboration, shared learning, and continued investment in the operational foundations needed to support the future of radiopharmaceutical medicine.

The industry’s ability to coordinate manufacturing, logistics, clinical operations, and patient care will play a decisive role in ensuring these life-changing treatments reach the patients who need them most.